1. Concurrent chemoradiotherapy with conventional fractionated radiotherapy and low-dose daily cisplatin plus weekly docetaxel for T2N0 glottic cancer.
- Author
-
Jun-ichi Saitoh, Katsuyuki Shirai, Masumi Imaeda, Atsushi Musha, Takanori Abe, Masato Shino, Yukihiro Takayasu, Katsumasa Takahashi, Kazuaki Chikamatsu, Takashi Nakano, Saitoh, Jun-Ichi, Shirai, Katsuyuki, Imaeda, Masumi, Musha, Atsushi, Abe, Takanori, Shino, Masato, Takayasu, Yukihiro, Takahashi, Katsumasa, Chikamatsu, Kazuaki, and Nakano, Takashi
- Subjects
- *
DOCETAXEL , *CISPLATIN , *SKIN inflammation , *CHEMORADIOTHERAPY , *RADIOTHERAPY , *HEMATOLOGIC agents , *RADIATION , *ANTINEOPLASTIC agents , *CANCER treatment , *DRUG administration , *DOSE-effect relationship in pharmacology , *HYDROCARBONS , *LONGITUDINAL method , *PROGNOSIS , *RADIATION doses , *SQUAMOUS cell carcinoma , *SURVIVAL , *TUMOR classification , *RETROSPECTIVE studies , *TUMOR treatment ,LARYNGEAL tumors - Abstract
Background: To assess the efficacy of concurrent chemoradiotherapy (CCRT) with daily low-dose cisplatin (CDDP) plus weekly docetaxel (DTX) for patients with T2N0 glottic cancer.Methods: Between January 2004 and December 2013, 62 treatment-naive patients with histologically proven T2N0 glottic cancer were treated with concurrent chemoradiotherapy. Radiation therapy (RT; 2 Gy daily fractions up to a total dose of 66 Gy) was administered in combination with daily low-dose CDDP (6 mg/m2, five times a week), plus weekly DTX (10 mg/m2) for up to 4 weeks from the commencement of RT.Results: Median duration of follow-up was 70 months. The actuarial 3-year and 5-year overall survival rates were 95% and 93%. The 3-year and 5-year cause-specific survival rates were both 100%. The actuarial 3-year and 5-year local control rates were 94% and 94%, respectively. Hematologic toxicity (neutoropenia of severity ≥ Grade 3) was observed in 8% of the patients, and non-hematologic toxicity (radiation mucositis of severity ≥ Grade 3) developed in one patient (2%). Radiation dermatitis of severity ≥ Grade 3 and laryngeal necrosis developed in one patient.Conclusion: CCRT with weekly DTX and low-dose CDDP appears to be a practical and safe modality and is expected to improve local control.Trial Registration: UMIN000025046 . Registered 1 October 2015, retrospectively registered. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF